Autocrine growth factor receptor antibodies and methods

A composition comprising an anti-PCDGF receptor antibody or antigen binding fragment and a cytotoxic molecule wherein said anti-PCDGF receptor antibody or antigen binding fragment is attached or capable of binding to said cytotoxic molecule.

A monoclonal anti-PCDGF receptor antibody or antigen binding fragment produced from a hybridoma cell line selected from the group consisting of 6G8 (ATCC Accession Number) and 5A8 (ATCC Accession Number PTA-5594).

A method of making an anti-idiotypic antibody or antigen binding fragment comprising immunizing an animal with the monoclonal anti-PCDGF antibody or antigen binding fragment produced from a hybridoma cell line selected from the group consisting of 6B3 (ATCC Accession Number PTA-5262), 6B2 (ATCC Accession Number PTA-5261), 6C12 (ATCC Accession Number PTA-5597), 5B4 (ATCC Accession Number PTA-5260), 5G6 (ATCC Accession Number PTA-5595), 4D1 (ATCC Accession Number PTA-5593), 3F8 (ATCC Accession Number PTA-5591), 3F5 (ATCC Accession Number PTA-5259), 3F4 (ATCC Accession Number PTA-5590), 3G2 (ATCC Accession Number PTA-5592), and 2A5 (ATCC Accession Number PTA-5589) isolating spleen cells from said immunized animals, producing hybridomas from said spleen cells, and screening said hybridomas to identify an anti-idiotypic antibody or antibody fragment capable of binding to the surface of a cell expressing the PCDGF receptor and interfering with the binding of PCDGF to the PCDGF receptor.

A method of making an anti-idiotypic antibody or antigen binding fragment comprising immunizing an animal with PCDGF, isolating spleen cells from said immunized animals, producing hybridomas from said spleen cells, and screening said hybridomas to identify an anti-idiotypic antibody or antibody fragment capable of binding to the surface of a cell expressing the PCDGF receptor and interfering with the binding of PCDGF to the PCDGF receptor.

A method of making an anti-PCDGF receptor antibody or antigen binding fragment comprising immunizing an animal with cells overexpressing the PCDGF receptor or cell fragments derived from cells overexpressing the PCDGF receptor, isolating spleen cells from said immunized animals, producing hybridomas from said spleen cells, and screening said hybridomas to identify an anti-PCDGF receptor antibody or antibody fragment capable of binding to the surface of a cell expressing the PCDGF receptor and interfering with the binding of PCDGF to the PCDGF receptor.